Plinabulin shows survival improvement and safety advantage in Asian NSCLC patients.

BeyondSpring's Plinabulin has shown consistent OS benefit in an Asian subset of patients with a strong HR of 0.69 for non-squamous patients, and a meaningful safety advantage in 2L/3L EGFR WT NSCLC. The results position Plinabulin as a late-stage candidate for survival improvement in this patient population. The data was presented at the European Society for Medical Oncology (ESMO) Asia Congress 2025.